Non-Drug Interventions (Q3679762)

From EU Knowledge Graph
Revision as of 16:44, 18 November 2021 by DG Regio (talk | contribs) (‎Changed label, description and/or aliases in en: translated_label)
Jump to navigation Jump to search
Project Q3679762 in France
Language Label Description Also known as
English
Non-Drug Interventions
Project Q3679762 in France

    Statements

    0 references
    27,016.0 Euro
    0 references
    180,850.0 Euro
    0 references
    14.94 percent
    0 references
    1 April 2015
    0 references
    31 May 2017
    0 references
    SATT AxLR
    0 references
    Les interventions non médicamenteuses (INM) regroupent trois catégories distinctes que sont les thérapies physiques, les thérapies psychologiques et la nutrition. Ces interventions visent à améliorer la qualité de vie d'un patient, sans pour autant se substituer aux thérapies classiques et conventionnelles. Elles s'adressent principalement aux personnes âgées et patients atteintes de maladies chroniques. Depuis 2010 les INM connaissent un essor considérable de la part des acteurs industriels, mais elles nécessitent encore la preuve de leur efficacité en termes de rapport coût / bénéfices. La plate-forme CEPS, créée au sein du laboratoire EPSYLON de Montpellier effectue ainsi des recherches sur des méthodes d'analyse de ce rapport coûts / avantages, en vue de les appliquer aux produits et services INM développés par les acteurs industriels. (French)
    0 references
    Non-drug interventions (NMIs) fall into three distinct categories: physical therapies, psychological therapies, and nutrition. These interventions aim to improve a patient’s quality of life, without replacing conventional and conventional therapies. They are aimed primarily at elderly people and patients with chronic diseases. Since 2010 NMIs have experienced considerable growth on the part of industrial players, but they still require proof of their cost-benefit effectiveness. The CEPS platform, created within the EPSYLON laboratory in Montpellier, thus carries out research on methods for analysing this cost-benefit ratio, with a view to applying them to INM products and services developed by industrial actors. (English)
    18 November 2021
    0 references

    Identifiers

    LR0008866
    0 references